{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:02:11Z","timestamp":1777917731387,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2001,11,1]],"date-time":"2001-11-01T00:00:00Z","timestamp":1004572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2001,11]]},"abstract":"<jats:sec>\n                    <jats:title>Aims and Background<\/jats:title>\n                    <jats:p>5-fluorouracil given by continuous infusion allows higher dose delivery, causes less myelosuppression and may interfere with repair of DNA damage caused by carboplatin. With this rationale, we conducted a phase II study to test the activity and toxicity of 5-fluorouracil and carboplatin given in continuous infusion to patients with advanced cancer and pretreated with at least two chemotherapy regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Forty patients with advanced tumors (21 colon, 4 stomach, 3 breast, 3 bladder, 3 ovary, and 6 at other sites) were entered in the trial. 5-fluorouracil (200 mg\/m\n                      <jats:sup>2)<\/jats:sup>\n                      and carboplatin (20 mg\/m\n                      <jats:sup>2)<\/jats:sup>\n                      were administered by continuous infusion from days 1 to 20, every 4 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All patients were assessable for response and toxicity. A total of 138 courses of chemotherapy were administered, with a mean of 3.5 per patient (range, 2-9). Toxicity, assessed using WHO criteria, was as follows: nausea and vomiting grade 2-3 in 34% of patients, alopecia grade 2-3 in 96%, and neutropenia grade 3-4 in 26%. One patient (2.5%) had a complete response to therapy and 7 (17.5%) had a partial response (response rate 20%; 95% Cl, 9.06-35.68%). Disease stability and progression occurred in 12 (30%) and 20 (50%) patients, respectively. Median time to progression was 5.6 months (range, 2.8-45.9+), with a median survival time of 7.7 months (range, 1.5-45.9+).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Outpatient treatment with a combination of 5-fluorouracil and carboplatin in continuous infusion was active as salvage treatment for advanced tumors and may give prolonged palliation of symptoms with manageable toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/030089160108700605","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T12:37:26Z","timestamp":1523882246000},"page":"383-387","source":"Crossref","is-referenced-by-count":1,"title":["5-fluorouracil-carboplatin Continuous Infusion as Salvage Chemotherapy in Advanced Cancer"],"prefix":"10.1177","volume":"87","author":[{"given":"Francesco","family":"Recchia","sequence":"first","affiliation":[{"name":"Divisione di Oncologia, Ospedale Civile, Avezzano;"},{"name":"\u201cFondazione Carlo Ferri\u201d, Monterotondo, Roma;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"De Filippis","sequence":"additional","affiliation":[{"name":"Divisione di Oncologia, Ospedale Civile, Avezzano;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Rosselli","sequence":"additional","affiliation":[{"name":"\u201cFondazione Carlo Ferri\u201d, Monterotondo, Roma;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Saggio","sequence":"additional","affiliation":[{"name":"Divisione di Oncologia, Ospedale Civile, Avezzano;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Piccinini","sequence":"additional","affiliation":[{"name":"Divisione di Oncologia, Ospedale Civile, Avezzano;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Rea","sequence":"additional","affiliation":[{"name":"\u201cFondazione Carlo Ferri\u201d, Monterotondo, Roma;"},{"name":"Chirurgia Oncologica, Universit\u00e0 degli Studi di L'Aquila, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2001,11,1]]},"reference":[{"key":"bibr1-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90472-6"},{"key":"bibr2-030089160108700605","first-page":"4413","volume":"42","author":"Calabro-Jones P.M.","year":"1982","journal-title":"Cancer Res"},{"key":"bibr3-030089160108700605","first-page":"3479","volume":"38","author":"MacMillan V.E.","year":"1978","journal-title":"Cancer Res"},{"key":"bibr4-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1259"},{"key":"bibr5-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00214-X"},{"key":"bibr6-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199506000-00017"},{"key":"bibr7-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.2.270"},{"key":"bibr8-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(88)90261-1"},{"key":"bibr9-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.100"},{"key":"bibr10-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1979253351"},{"key":"bibr11-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1007\/BF00173643"},{"key":"bibr12-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.1987.tb00557.x"},{"key":"bibr13-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"bibr14-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"bibr15-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890201)63:3<419::AID-CNCR2820630303>3.0.CO;2-Z"},{"key":"bibr16-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1007\/BF01810577"},{"key":"bibr17-030089160108700605","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860315)57:6<1105::AID-CNCR2820570607>3.0.CO;2-W"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089160108700605","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089160108700605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:21:37Z","timestamp":1777659697000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/030089160108700605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["10.1177\/030089160108700605"],"URL":"https:\/\/doi.org\/10.1177\/030089160108700605","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11]]}}}